Soluble guanylate cyclase (sGC) is a signal-transduction enzyme activated by nitric oxide (NO) and plays a key role in a variety of physiological processes such as vasodilatation, antiaggregation, antiproliferation and neuronal signaling as well as in a variety of disorders of these functions. Current therapies that involve the use of organic nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomolecules and lack of response and the development of tolerance [1, 2] . Compounds that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages.
High throughput screening led to the identification of a series of dicarboxlic acids as potent sGC activators. Lead structure 1 showed promising in vitro potency (sGC over- Discovery of sGC activators via ultra-high throughput screening using sGC-overexpressing CHO cell lines Figure 1 Discovery of sGC activators via ultra-high throughput screening using sGC-overexpressing CHO cell lines. expressing CHO-cells and relaxation of precontracted rabbit arteria saphena rings) and haemodynamic effects in anaesthetized rats (Fig. 1) . Extensive chemical derivatization resulted in conclusive structure activity relationships, which will be presented. Eventually, optimization led to the discovery of BAY 58-2667, a highly potent sGC activator which is currently in clinical trials in patients for the treatment of acute decompensated chronic heart failure.
